Skip to main content
MB

Mojave Bio

This company manufactures assay reagents using a unique amber glass technology that encapsulates pre-formulated biologic reagents. This technology automates and standardizes workflows for biopharmaceutical manufacturing and cell therapy, applicable to antibodies and enzymes.

San Carlos, Venezuela310+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Complex biochemical assays in biopharmaceutical manufacturing and cell therapy often require manual workflows, leading to inconsistencies and increased risk of errors. Maintaining reagent quality and stability, especially for extended clinical trials, poses a significant challenge.

Solution

Mojave Bio offers pre-formulated biologic reagents encapsulated in a proprietary "AmberGlass" technology, automating and standardizing workflows for biopharmaceutical manufacturing and cell therapy. The AmberGlass technology forms a thin, amorphous layer that adheres to the surface of the container, preserving the conformational integrity of the reagents. This encapsulation enables long-term room temperature storage and ensures consistency across batches, simplifying complex assays and improving reproducibility. The technology is customizable to meet specific requirements for various biochemical assays.

Target Audience

The primary customers are QA/QC laboratories, clinical trial organizations, and biomanufacturing facilities seeking to streamline reagent handling and ensure consistency in complex assays.

Features

  • AmberGlass technology encapsulates pre-formulated and standardized biologic reagents.
  • Reagents maintain stability and conformational integrity for years at room temperature.
  • Applicable to master mixes of antibodies, enzymes (including PCR master mix), nucleic acids, and fixed mammalian cells.
  • Simplifies and automates workflows for QA/QC labs using unitized and standardized assay reagents.
  • Enables the use of large, single-batch reagents for the duration of clinical trials.
  • Facilitates an integrated system approach for bioreactors by delivering growth factors in a standardized cartridge format.
This profile is AI-generated and may contain inaccuracies.